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A B S T R A C T
Background: Acute varicella zoster virus (VZV) replication in shingles is accompanied by VZV antibody boosting.
It is unclear whether persisting virus shedding a ects antibody levels.ﬀ
Objectives: To investigate the relationship between VZV viral load and antibody titres in shingles patients during
six months following diagnosis and assess whether VZV antibody titre could discriminate patients with recent
shingles from healthy population controls.
Study design: A prospective study of 63 patients with active zoster. Blood samples were collected at baseline, one,
three and six months to measure VZV DNA and IgG antibody titre. We compared VZV antibody titres of zoster
patients and 441 controls.
Results: In acute zoster, viral load was highest at baseline and declined gradually over the following six months.
Mean antibody titres rose fourfold, peaking at one month and remaining above baseline levels throughout the
study. Antibody levels at one, three and six months after zoster were moderately correlated with baseline but not
subsequent viral load. Regarding use of antibody titres to identify recent shingles, to achieve 80% sensitivity,
speci city would be 23.4%, 67.7%, 64.8% and 52.6%, at baseline, visit 2, 3 and 4 respectively, whilst to achieveﬁ
80% speci city, sensitivity would be 28.3%, 66.1%, 52.6%, 38.6%, at baseline, visit 2, 3 and 4 respectively.ﬁ
Conclusions: Clinical VZV reactivation boosted VZV antibody levels and the level of boosting was dependent
upon baseline viral replication. While antibody titres could discriminate patients with shingles 1 6 months–
earlier from blood donor controls, there was a large trade-o between sensitivity and speci city.ﬀ ﬁ
1. Background
Primary infection with varicella zoster virus (VZV) causes chick-
enpox, following which the virus establishes latency. It reactivates in up
to 25% of individuals to cause the painful dermatomal rash known as
shingles (herpes zoster). During chickenpox or shingles, viral DNA is
detectable in skin lesions, blood and saliva [ ]. Viral replication is1,2
accompanied by boosting of VZV antibodies consistent with antigenic,
or endogenous, boosting. Few data exist, however, con rming the re-ﬁ
lationship between viral load and antibody titres during, and following,
acute clinical VZV disease.
The extent to which the presence of persisting viral DNA in blood or
saliva indicates active viral replication likely to induce an immune re-
sponse is also unclear. Immunocompetent children with chickenpox
clear viral DNA rapidly so that it is no longer detectable two weeks after
the rash has healed [ ]. In contrast, VZV DNA has been detected in3
blood for up to 6 months following shingles, albeit with falling loads
[ ]. Asymptomatic shedding of VZV in saliva occurs more frequently in4
individuals who are immune disadvantaged [ ]. Better under-5 7–
standing of the spectrum of VZV reactivation is needed to inform use of
biological markers of VZV reactivation in research.
2. Objectives
We aimed to investigate the relationship between VZV DNA levels
and antibody titres by following acute shingles patients over 6 months,
and to assess whether VZV antibody titre could discriminate patients
with recent shingles from population controls for future research.
3. Study design
3.1. Study participants
Patients with shingles presenting to GPs in London between 2001
and 2003 were recruited consecutively for a prospective cohort study of
disease burden, clinical and laboratory indices of zoster (described
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elsewhere) [ ]. Diagnosis was con rmed through detection of VZV DNA4 ﬁ
from vesicle uid by PCR in patients with clinically-suspected zoster.ﬂ
Patients completed a baseline survey that included demographic in-
formation, history of chickenpox and previous shingles episodes, im-
mune status (including underlying illnesses and current treatment) and
detailed information about the shingles episode (timing, symptoms,
medications). Blood samples were taken at baseline, one, three and six
months to measure IgG antibody titre and viral load. Blood samples
from healthy blood donors from a single time-point were also collected.
3.2. Viral load and antibody measurements
Viral load was determined through detection and quanti cation ofﬁ
VZV DNA from whole blood. DNA extraction was performed using a
QIAamp DNA blood mini kit (Qiagen Ltd, United Kingdom), with eluted
DNA stored at 20 °C. VZV DNA was quanti ed using a real-time PCR− ﬁ
assay, which had a sensitivity threshold of < 10 VZV copies/ l(10).μ
VZV IgG antibody titres were measured using a validated in-house time
resolved uorescence immunoassay [ ]. Serum dilutions were tested inﬂ 8
duplicate and the Europium counts obtained were interpolated against
a standard curve of British Standard VZV antibody (NIBSC 90/690)
covering the VZV IgG range 0.39 50 mIU/ml. Sera producing Europium–
counts outwith the curve were retested at appropriate dilutions. Du-
plicate results were averaged and multiplied by the dilution factor to
obtain a nal mean antibody level.ﬁ
3.3. Statistical methods
We recoded implausible IgG values above the 95th blood donor
percentile as missing (n = 23) and log transformed viral load and an-
tibody titre to provide a normal distribution. We summarised the
median, IQR and mean of the log transformed viral load and antibody
titre at each time point. As there was no evidence of a non-linear as-
sociation between logged mean viral DNA load and logged mean anti-
body titre we used Pearson s correlation coe cients to investigate as-’ ﬃ
sociations between these variables at the same and subsequent time
points for shingles patients. These relationships were further explored
using multivariable linear regression models. Potential confounding
e ects of age, sex, ethnicity, immunosuppression, days since rash onset,ﬀ
prodromal symptoms, disseminated rash and antiviral treatment were
investigated using causal diagrams. Variables were retained if they
were theoretically relevant confounders, and/or associated with both
outcome and exposure at the 10% signi cance level using a forwardﬁ
selection approach.
To determine whether recent zoster could be identi ed from anti-ﬁ
body levels, we undertook ROC analysis, comparing antibody levels in
healthy controls with zoster patients. Antibody cut-o values (not onﬀ
the log scale) to achieve 80% and 90% sensitivity or speci city, wereﬁ
calculated for each visit separately (along with the corresponding sen-
sitivity or speci city), after adjusting for age and sex.ﬁ
4. Results
The study comprised 63 patients with shingles, with a median age of
56 years (IQR 37 71 years) of whom 34 (54.0%) were male, and 441–
blood donor controls ( ).Table 1
Viral load among shingles patients was highest at baseline and
lowest at six months. Antibody titres rose from baseline to be maximal
at one month then gradually declined, although titres remained ele-
vated above baseline levels at six months ( ).Fig. 1
Viral load at baseline was positively associated with antibody titres
at one, three and six months as shown in Fig. 2, although the strength of
the associations were small to moderate. There was some evidence
(P = .033) of a small negative correlation (r = 0.285) between viral−
load at one month and antibody titre at six months, but there were
otherwise no signi cant associations between viral load measurementsﬁ
taken after baseline and later antibody titres. In multivariable linear
regression models adjusted for age, sex, ethnicity and immune status,
higher baseline viral load was associated with a higher antibody titre at
one, three and six months ( ).Fig. 2
Antibody titre was higher in shingles patients at 1, 3 and 6 months
from baseline, compared to controls; median log antibody titre was
3.16 (IQR: 2.92 3.45) among controls. ROC analysis ( ) demon-– Fig. 3
strated that to achieve 80% sensitivity, speci city would be 23.4%,ﬁ
67.7%, 64.8% and 52.6%, whilst to achieve 80% speci city, sensitivityﬁ
would be 28.3%, 66.1%, 52.6% and 38.6% at baseline, visit 2, 3 and 4
respectively. The best obtainable speci city, at 90% sensitivity, wasﬁ
59%, and the best obtainable sensitivity, at 90% speci city, was 39%ﬁ
(data not shown).
5. Discussion
We showed that baseline, rather than subsequent viral load was the
strongest predictor of antibody titre at one, three and six months after
an acute shingles episode. Antibody titres remained persistently ele-
vated in shingles patients compared to healthy blood donors for at least
six months, with the greatest discrimination between groups occurring
at one month post shingles. Antibody titres could discriminate patients
with recent shingles from healthy controls, however there was a sig-
ni cant trade-o between sensitivity and speci city.ﬁ ﬀ ﬁ
Reactivation of latent VZV is largely kept in check through cell-
mediated immunity [ ], with antibodies playing very little role in VZV9
control. Individuals with severe clinical VZV reactivation including
those who develop post-herpetic neuralgia often have high antibody
titres, which are believed to correlate with more widespread VZV re-
plication [ ]. Our ndings are consistent with this hypothesis. The10 ﬁ
lack of association found between viral loads at one, three and six
months and antibody titres at the same and subsequent time points
suggests that persistence of serum VZV DNA after shingles may be a
function of decay rather than ongoing replication, although this ndingﬁ
Table 1
Baseline characteristics of shingles patients and blood donors.
Variable Group, frequency (%)
Shingles patients (N = 63) Blood donors (N = 441)
Age, median (IQR), yrs 56 (37 71) 42 (29 51)– –
Sex
Male 34 (54.0) 207 (46.9)
Female 29 (46.0) 234 (53.1)
Ethnicitya






Yes 7 (11.1) Data not available
No 56 (88.9)
Rash age, days
0 2 7 (11.1) N/A–
3 4 21 (33.3)–
5 6 22 (34.9)–
6+ 13 (20.6)
Prodromal symptoms
Yes 46 (73.0) N/A
No 17 (27.0)
Disseminated rash
Yes 7 (11.7) N/A
No 53 (88.3)
Missing 3 ( )–
Antiviral medication for shingles
Yes 43 (68.3) N/A
No 20 (31.7)
a Modelled as Caucasian versus Non Caucasian .‘ ’ ‘ ’
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needs to be tested in other larger populations.
Antibody titre cut-o values could be used to identify patients withﬀ
shingles 1 6 months previously, but with a large trade-o between– ﬀ
sensitivity and speci city. Whether researchers choose to set cut oﬁ ﬀ
values to achieve a high sensitivity e.g. when using antibody titre as an
initial screening test for recent shingles, or to be highly speci c e.g. in aﬁ
test aimed at diagnostic con rmation, will depend on the nature andﬁ
context of their research.
This study was limited by relatively small numbers of patients. Data
on other potential confounding factors such as ethnicity and immune
status in blood donors was lacking, so only age and sex were accounted
for in the shingles patient-blood donor analysis. Nevertheless, as these
factors were not associated with antibody titre in shingles patients,
results are unlikely to have been notably a ected.ﬀ
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Fig. 2. Association between log viral load and antibody titre, at the same and various time points: Pearson correlation coe cients and coe cients from multivariableﬃ ﬃ
linear regression models displayed.
Note: Adjusted coe cients represent the e ect of a one unit change in the variable value on the log mean antibody titre, adjusted for age, sex, ethnicity andﬃ ﬀ
immunosuppression status.
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In conclusion, there is evidence for endogenous boosting of VZV
antibody levels by clinical VZV reactivation and the level of boosting is
dependent upon baseline viral replication. Additionally, antibody titres
could discriminate post-shingles patients from healthy controls, al-
though whether to prioritise speci city or sensitivity would depend onﬁ
the study question.
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*If the VZV IgG antibody titre value is greater
than or equal to the cut-o , then the individual isﬀ
declared positive (a ected) by this cut-o ap-ﬀ ﬀ
proach, else negative (healthy), and these are
compared to the actual status to determine sen-
sitivity and speci city.ﬁ
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